메뉴 건너뛰기




Volumn 67, Issue 5, 2009, Pages 520-526

Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

Author keywords

CETP inhibition; LDL C; Simvastatin

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DRUG DERIVATIVE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; SIMVASTATIN ACID; UNCLASSIFIED DRUG;

EID: 65349191226     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03385.x     Document Type: Article
Times cited : (38)

References (18)
  • 10
    • 65349180621 scopus 로고    scopus 로고
    • Merck & Co., Inc. Whitehouse Station, NJ. Merck & Co., Inc.
    • Merck & Co., Inc. Zocor (Simvastatin) Product Circular. Whitehouse Station, NJ : Merck & Co., Inc., 2004.
    • (2004) Zocor (Simvastatin) Product Circular.
  • 11
    • 0026341760 scopus 로고
    • Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia
    • Mölgaard J, Lundh BL, van Schenck H, Olsson AG. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia. Atherosclerosis 1991 91 : S21 8.
    • (1991) Atherosclerosis , vol.91 , pp. 21-8
    • Mölgaard, J.1    Lundh, B.L.2    Van Schenck, H.3    Olsson, A.G.4
  • 12
    • 0031670167 scopus 로고    scopus 로고
    • Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
    • Kantola T, Kivistö KT, Neuvonen PT. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998 64 : 177 82.
    • (1998) Clin Pharmacol Ther , vol.64 , pp. 177-82
    • Kantola, T.1    Kivistö, K.T.2    Neuvonen, P.T.3
  • 15
    • 33846505675 scopus 로고    scopus 로고
    • Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated: Results from a phase 2 dose-ranging clinical trial
    • Suppl.
    • Thuren T, Longcore A, Powell C. Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated: results from a phase 2 dose-ranging clinical trial. Circulation 2005 112 (17 Suppl. II-179.
    • (2005) Circulation , vol.112 , Issue.17 , pp. 179
    • Thuren, T.1    Longcore, A.2    Powell, C.3
  • 17
    • 0024307596 scopus 로고
    • Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia
    • Mölgaard J, von Schenck H, Olsson AG. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia. Eur J Clin Pharmacol 1989 36 : 455 60.
    • (1989) Eur J Clin Pharmacol , vol.36 , pp. 455-60
    • Mölgaard, J.1    Von Schenck, H.2    Olsson, A.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.